Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Company Overview

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) disorders. Headquartered in Rockville, Maryland, Supernus concentrates on branded therapies for conditions such as epilepsy, attention-deficit/hyperactivity disorder (ADHD), migraine and Parkinson’s disease. Since its inception in 2008, the company has built a portfolio of extended‐release formulations and novel drug delivery technologies aimed at improving patient outcomes and adherence.

The company’s marketed products include Trokendi XR® and Oxtellar XR® for epilepsy, Qelbree® (viloxazine hydrochloride) for ADHD in children and adults, and Xadago® (safinamide) for Parkinson’s disease. Supernus invests in research and development to advance its pipeline, which encompasses both next‐generation formulations of existing therapies and new molecular entities designed to address unmet needs in neurology. Collaborations with academic institutions and contract research organizations support the company’s efforts to expand its clinical programs.

Supernus went public in 2013 and has grown its commercial infrastructure primarily across the United States. The company leverages strategic partnerships to distribute certain products internationally, enhancing its global reach. Supernus is known for its patient‐centric approach, offering support programs that provide education, reimbursement assistance and other resources to individuals and caregivers managing chronic CNS conditions.

Under the leadership of President and Chief Executive Officer Suvarna Patel and a seasoned executive team, Supernus continues to refine its strategic focus on neuroscience. The board of directors and senior management bring extensive experience in pharmaceutical development, regulatory affairs and commercialization, positioning the company for sustained growth in the CNS therapeutic area.

Key Stats

• Today's Range: $31.75 to $32.55
• 50-Day Range: $30.96 to $33.43
• 52-Week Range: $25.66 to $40.28
• Volume: 212,566 shs
• Average Volume: 477,192 shs
• Market Capitalization: $1.79 billion
• P/E Ratio: 28.82
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Hold

Supernus Pharmaceuticals Stock Analysis - MarketRank™

Supernus Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 1564th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Supernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Supernus Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -39.50%

Earnings Growth

Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Supernus Pharmaceuticals is 28.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Supernus Pharmaceuticals is 28.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.60.

Price to Book Value per Share Ratio

Supernus Pharmaceuticals has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.61% of the float of Supernus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Supernus Pharmaceuticals has recently decreased by 4.73%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Supernus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Supernus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

7.61% of the float of Supernus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Supernus Pharmaceuticals has recently decreased by 4.73%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.81

News Sentiment

Supernus Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Supernus Pharmaceuticals this week, compared to 6 articles on an average week.

MarketBeat Follows

Only 1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.80% of the stock of Supernus Pharmaceuticals is held by insiders.

SUPN Stock Analysis - Frequently Asked Questions

How have SUPN shares performed this year?

Supernus Pharmaceuticals' stock was trading at $36.16 at the beginning of 2025. Since then, SUPN shares have decreased by 11.5% and is now trading at $31.9950.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its earnings results on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm's quarterly revenue was up 14.2% compared to the same quarter last year.
Read the conference call transcript.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 7/04/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SUPN
• CIK: 1356576
• Web: www.supernus.com
• Phone: (301) 838-2500
• Fax: 301-838-2501
• Employees: 580
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +12.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.11
• Trailing P/E Ratio: 28.82
• Forward P/E Ratio: 13.44
• P/E Growth: N/A
• Net Income: $73.86 million
• Net Margins: 9.27%
• Pretax Margin: 13.74%
• Return on Equity: 12.23%
• Return on Assets: 9.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.44
• Quick Ratio: 2.26

Sales & Book Value

• Annual Sales: $661.82 million
• Price / Sales: 2.71
• Cash Flow: $4.16 per share
• Price / Cash Flow: 7.69
• Book Value: $18.76 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 55,990,000
• Free Float: 51,063,000
• Market Cap: $1.79 billion
• Optionable: Optionable
• Beta: 0.70